Skip to main content

Main menu

  • Home
  • Content
    • Current Issue
    • Ahead of Print
    • Past Issues
    • Supplements
    • Article Type
  • Specialty
    • Articles by Specialty
  • CME/MOC
    • Articles
    • Calendar
  • Info For
    • Manuscript Submission
    • Authors & Reviewers
    • Subscriptions
    • About CCJM
    • Contact Us
    • Media Kit
  • Conversations with Leaders
  • Conference Coverage
    • Kidney Week 2024
    • CHEST 2024
    • ACR Convergence 2023
    • Kidney Week 2023
    • ObesityWeek 2023
    • IDWeek 2023
    • CHEST 2023
    • MDS 2023
    • IAS 2023
    • ACP 2023
    • AAN 2023
    • ACC / WCC 2023
    • AAAAI Meeting 2023
    • ACR Convergence 2022
    • Kidney Week 2022
    • AIDS 2022
  • Other Publications
    • www.clevelandclinic.org

User menu

  • Register
  • Log in

Search

  • Advanced search
Cleveland Clinic Journal of Medicine
  • Other Publications
    • www.clevelandclinic.org
  • Register
  • Log in
Cleveland Clinic Journal of Medicine

Advanced Search

  • Home
  • Content
    • Current Issue
    • Ahead of Print
    • Past Issues
    • Supplements
    • Article Type
  • Specialty
    • Articles by Specialty
  • CME/MOC
    • Articles
    • Calendar
  • Info For
    • Manuscript Submission
    • Authors & Reviewers
    • Subscriptions
    • About CCJM
    • Contact Us
    • Media Kit
  • Conversations with Leaders
  • Conference Coverage
    • Kidney Week 2024
    • CHEST 2024
    • ACR Convergence 2023
    • Kidney Week 2023
    • ObesityWeek 2023
    • IDWeek 2023
    • CHEST 2023
    • MDS 2023
    • IAS 2023
    • ACP 2023
    • AAN 2023
    • ACC / WCC 2023
    • AAAAI Meeting 2023
    • ACR Convergence 2022
    • Kidney Week 2022
    • AIDS 2022
Contributions

Treatment of psoriasis with chronic subcutaneous administration of somatostatin analog 201-995 (Sandostatin)

I. An open-label pilot study

Charles Camisa, MD, Thomas M. O’Dorisio, MD, Ronald F. Maceyko, MD, Gretchen E. Schacht, MD, Hagop S. Mekhjian, MD and Brent A. Howe, BS
Cleveland Clinic Journal of Medicine January 1990, 57 (1) 71-76;
Charles Camisa
Department of Dermatology, The Cleveland Clinic Foundation
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Thomas M. O’Dorisio
Department of Internal Medicine, Ohio State University Hospitals, Columbus, Ohio
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ronald F. Maceyko
Department of Dermatology, The Cleveland Clinic Foundation
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gretchen E. Schacht
Department of Internal Medicine, Ohio State University Hospitals, Columbus, Ohio
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hagop S. Mekhjian
Department of Internal Medicine, Ohio State University Hospitals, Columbus, Ohio
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Brent A. Howe
Department of Internal Medicine, Ohio State University Hospitals, Columbus, Ohio
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
  • PDF
Loading

ABSTRACT

Increased levels of human growth hormone (HGH) may correlate with the severity of psoriasis and native somatostatin (SRIF) may improve it by inhibiting HGH release. The synthetic SRIF analog, SMS 201-995, is a potent and long-lasting HGH inhibitor. Nine patients with chronic plaque psoriasis completed 12 weeks of open treatment with SMS 201-995. Overall improvement was minimal to marked in six patients and unchanged in three; none worsened. Means of 24-hour pooled HGH (1.7 ± 0.7 μg/L) and fasting plasma somatomedin-C (SM - C) (0.45 ± 0.22 U/mL) were normal at baseline and were not significantly altered by treatment. A high frequency of gastrointestinal side effects occurred, but no patient discontinued treatment because of them. SMS 201-995 may be a useful therapy for psoriasis, but its mechanism of action is unknown. Double-blind placebo-controlled trials are currently in progress to confirm the efficacy of SMS 201-995 in psoriasis.

INDEX TERMS
  • Psoriasis
  • Somatostatin
  • Somatotropin
  • Copyright © 1990 The Cleveland Clinic Foundation. All Rights Reserved.
PreviousNext
Back to top

In this issue

Cleveland Clinic Journal of Medicine: 57 (1)
Cleveland Clinic Journal of Medicine
Vol. 57, Issue 1
1 Jan 1990
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Cleveland Clinic Journal of Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Treatment of psoriasis with chronic subcutaneous administration of somatostatin analog 201-995 (Sandostatin)
(Your Name) has sent you a message from Cleveland Clinic Journal of Medicine
(Your Name) thought you would like to see the Cleveland Clinic Journal of Medicine web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Treatment of psoriasis with chronic subcutaneous administration of somatostatin analog 201-995 (Sandostatin)
Charles Camisa, Thomas M. O’Dorisio, Ronald F. Maceyko, Gretchen E. Schacht, Hagop S. Mekhjian, Brent A. Howe
Cleveland Clinic Journal of Medicine Jan 1990, 57 (1) 71-76;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Treatment of psoriasis with chronic subcutaneous administration of somatostatin analog 201-995 (Sandostatin)
Charles Camisa, Thomas M. O’Dorisio, Ronald F. Maceyko, Gretchen E. Schacht, Hagop S. Mekhjian, Brent A. Howe
Cleveland Clinic Journal of Medicine Jan 1990, 57 (1) 71-76;
Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Linkedin Share Button

Jump to section

  • Article
  • Info & Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • Panic disorder and social phobia: Current treatments and new strategies
  • Anticonvulsants for neuropathic pain and detoxification
  • Bipolar disorder: Current treatments and new strategies
Show more Contributions

Similar Articles

Keywords

  • Psoriasis
  • Somatostatin
  • Somatotropin

Navigate

  • Current Issue
  • Past Issues
  • Supplements
  • Article Type
  • Specialty
  • CME/MOC Articles
  • CME/MOC Calendar
  • Media Kit

Authors & Reviewers

  • Manuscript Submission
  • Authors & Reviewers
  • Subscriptions
  • About CCJM
  • Contact Us
  • Cleveland Clinic Center for Continuing Education
  • Consult QD

Share your suggestions!

Copyright © 2025 The Cleveland Clinic Foundation. All rights reserved. The information provided is for educational purposes only. Use of this website is subject to the website terms of use and privacy policy. 

Powered by HighWire